Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill shows promise for vitiligo in major trial

NCT ID NCT06113471

Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a daily pill called povorcitinib to see if it can safely bring back skin color in people with nonsegmental vitiligo, a condition where white patches appear on the skin. About 450 adults will receive either the drug or a placebo for 52 weeks. The main goal is to measure at least a 75% improvement in facial skin color.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

450 people

The number who actually took part.

Started

Nov 2023

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged ≥ 18 years. * Clinical diagnosis of nonsegmental vitiligo and meet the following: * T-BSA ≥ 5% * T-VASI score ≥ 4 * F-BSA ≥ 0.5% * F-VASI score ≥ 0.5 * Agreement to discontinue all agents and procedures used to treat vitiligo from screening through the final safety follow-up visit. * Willingness to avoid pregnancy or fathering children. Exclusion Criteria: * Other forms of vitiligo or skin depigmentation disorders. * Clinically significant abnormal TSH or free T4 at screening. * Use of laser or phototherapy within 8 weeks and dihydroxyacetone within 4 weeks prior to Day 1. * Current or past use of the depigmenting agent monobenzyl ether of hydroquinone including Benoquin®. * History of melanocyte-keratinocyte transplantation procedure or other surgical treatment for vitiligo. * Spontaneous and significant repigmentation within 6 months prior to screening. * Women who are pregnant, considering pregnancy, or breast feeding. * Medical history including thrombocytopenia, coagulopathy or platelet dysfunction; venous and arterial thrombosis, deep vein thrombosis, pulmonary embolism, stroke, moderate to severe heart failure, cerebrovascular accident, myocardial infarction, or other significant cardiovascular diseases; Q-wave interval abnormalities; disseminated herpes zoster or recurrent dermatomal herpes zoster; disseminated herpes simplex; chronic/recurrent infections; malignancies. * Evidence of infection with TB, HBV, HCV or HIV. * History of failure to JAK inhibitor treatment of any inflammatory disease. * Laboratory values outside of the protocol-defined ranges. Other protocol-defined Inclusion/Exclusion Criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nonsegmental vitiligo are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

generalized vitiligo vitiligo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Nonsegmental vitiligo

Contacts and locations

Locations

  • 28 Diagnostic and Consultative Center

    Sofia, 01528, Bulgaria

  • Advanced Medical Research Pc

    Sandy Springs, Georgia, 30328, United States

  • Aesthetic and Dermatology Center

    Rockville, Maryland, 20850, United States

  • Aleksandrovska University Hospital

    Sofia, 01431, Bulgaria

  • Alergo-Med Specjalistyczna Przychodnia Lekarska Sp. Z O.O.

    Tarnów, 33-100, Poland

  • Allcutis Research, Llc

    Portsmouth, New Hampshire, 03801, United States

  • Ambulatory For Specialized Medical Care - Individual Practice For Specialized Medical Care - Skin An

    Sofia, 01407, Bulgaria

  • Asst Degli Spedali Civili Di Brescia

    Brescia, 25123, Italy

  • Azienda Policlinico Vittorio Emanuele

    Catania, 95123, Italy

  • British Columbia'S Centre For Dermatologic Science - the Skin Care Centre

    Vancouver, British Columbia, V5Z 4E8, Canada

  • C2 Research Center, Llc

    Montgomery, Alabama, 36117, United States

  • Cabinet Medical- Chemin de Paradis

    Martigues, 13500, France

  • Callender Dermatology and Cosmetic Center

    Glenn Dale, Maryland, 20769, United States

  • Center For Dermatology Clinical Research, Inc

    Fremont, California, 94538, United States

  • Centre Hospitalier - Le Mans

    Le Mans, 72037, France

  • Centre Hospitalier Universitaire de Nice,Hopital L Archet

    Nice, 06200, France

  • Centre de Recherche Dermatologique de Quebec

    Québec, Quebec, G1V4X7, Canada

  • Centrum Medyczne Evimed

    Warsaw, 02-625, Poland

  • Centrum Medyczne Oporow

    Wroclaw, 52-416, Poland

  • Charite Universitaetsmedizin Berlin - Campus Charite Mitte

    Berlin, 10117, Germany

  • Chru Morvan/Chu Brest Hopital Morvan

    Brest, 29200, France

  • Clinical Trials Research Institute

    Thousand Oaks, California, 91320, United States

  • DERMEDGE

    Mississauga, Ontario, L4Y 4C5, Canada

  • Debreceni Egyetem

    Debrecen, 04032, Hungary

  • Delricht Research

    Baton Rouge, Louisiana, 70809, United States

  • Dermatologische Gemeinschaftspraxis

    Mahlow, 15831, Germany

  • Dermatology Clinical Research Center of San Antonio

    San Antonio, Texas, 78229, United States

  • Dermatology Research Associates

    Los Angeles, California, 90045, United States

  • Dermatology Treatment and Research Center

    Dallas, Texas, 75230, United States

  • Dermatology and Surgery Specialists of North Atlanta

    Marietta, Georgia, 30068, United States

  • Dermmedica Sp. Z O.O.

    Wroclaw, 51-318, Poland

  • Dermoklinika Centrum Medyczne S.C., M. Kierstan, J. Narbutt, A. Lesiak

    Lodz, 90-436, Poland

  • Driven Research Llc

    Coral Gables, Florida, 33134, United States

  • Dundee Dermatology

    West Dundee, Illinois, 60118, United States

  • Fachklinik Bad Bentheim

    Bad Bentheim, 481455, Germany

  • First Oc Dermatology Research Inc

    Fountain Valley, California, 92708-3701, United States

  • Florida Academic Centers Research and Education Llc

    Coral Gables, Florida, 33134, United States

  • Fondazione Irccs Ca Granda Ospedale Maggiore

    Milan, 20122, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli Irccs

    Rome, 00168, Italy

  • Futuremeds Targowek Centrum Medyczne Amed Warszawa Targowek

    Wrocaw, 03-291, Poland

  • Heights Dermatology and Aesthetic Center

    Houston, Texas, 77008, United States

  • Henry Ford Health System

    Detroit, Michigan, 48202, United States

  • Hopital Charles Nicolle

    Rouen, 76031, France

  • Indiana University School of Medicine Iusm Indianapolis

    Indianapolis, Indiana, 46202-3082, United States

  • Innovative Dermatology: Legacy Medical Village

    Plano, Texas, 75024, United States

  • Ipswich Hospital, East Suffolk and North Essex Nhs Foundation Trust

    Ipswich, IP4 5PD, United Kingdom

  • Irccs Istituto Clinico Humanitas

    Rozzano, 20089, Italy

  • Klinika Ambroziak Sp. Z O.O.

    Warsaw, 02-953, Poland

  • Laser Clinic

    Szczecin, 70-332, Poland

  • Lynderm Research Inc

    Markham, Ontario, L3P 1X2, Canada

  • Markusovszky Teaching Hospital

    Szombathely, Hungary

  • Marvel Clinical Research Llc

    Huntington Beach, California, 92647, United States

  • Medical Center Asklepii Ood

    Dupnitsa, 02600, Bulgaria

  • Medical Center Unimed Eood

    Sliven, 05308, Bulgaria

  • Metabolic Research Institute Inc

    West Palm Beach, Florida, 33401, United States

  • Niepubliczny Zaklad Opieki Zdrowotnej Dermed Centrum Medyczne Sp. Z O.O.

    Lodz, 90-265, Poland

  • Nottingham University Hospitals - Treatment Center

    Nottingham, NG7 2FT, United Kingdom

  • Oregon Medical Research Center, Pc

    Portland, Oregon, 97223, United States

  • Orvostudomanyi Kutato Es Fejleszto Kft

    Debrecen, 04027, Hungary

  • Pediatric Skin Research Llc

    Coral Gables, Florida, 33146, United States

  • Premier Clinical Research

    Spokane, Washington, 99202, United States

  • Pro Familia Altera Sp. Z O.O.

    Katowice, 40-648, Poland

  • Provita Sp.Zo.O. Centrum Medyczne Angelius

    Katowice, 40-611, Poland

  • Prywatny Gabinet Dermatologiczny Elzbieta Klujszo

    Kielce, 25-316, Poland

  • Remington-Davis Clinical Research

    Columbus, Ohio, 43215, United States

  • Research Toronto

    Toronto, Ontario, M4W 2N4, Canada

  • Royal Wolverhampton Nhs Trust

    Walsall, WS2 9PS, United Kingdom

  • Royalderm Agnieszka Nawrocka

    Warsaw, 02-692, Poland

  • Skin Care Research, Llc

    Boca Raton, Florida, 33486, United States

  • Synexus Gdynia

    Gdynia, 81-537, Poland

  • Synexus Polska Sp. Z O.O. Oddzial W Gdansku

    Gdansk, 80-382, Poland

  • Synexus Polska Sp. Z O.O. Oddzial We Wroclawiu

    Wroclaw, 50-088, Poland

  • Texas Dermatology and Laser Specialists

    San Antonio, Texas, 78218, United States

  • Toronto Research Centre

    Toronto, Ontario, M3H 5Y8, Canada

  • Total Vein and Skin Llc

    Boynton Beach, Florida, 33437, United States

  • Twoja Przychodnia - Szczecinskie Centrum Medyczne

    Szczecin, 71-434, Poland

  • Universitaetsklinikum Hamburg-Eppendorf

    Hamburg, 20246, Germany

  • Universitaetsklinikum Muenster

    Münster, 48149, Germany

  • University Hospital Carl Gustav Carus

    Dresden, 01307, Germany

  • University Hospitals of Leicester-Leicester Royal Infirmary (Lri)

    Leicester, LE1 5WW, United Kingdom

  • University of Alabama At Birmingham Hospital-Whitaker Clinic

    Birmingham, Alabama, 35294-0007, United States

  • University of Texas, Md Anderson Cancer

    Houston, Texas, 77030, United States

  • Velocity Clinical Research, Skierniewice

    Skierniewice, 96-100, Poland

  • Vitiligo & Pigmentation Institute of Southern California

    Los Angeles, California, 90036-5609, United States

  • Weill Cornell Medical College

    New York, New York, 10065, United States

  • Whipps Cross University Hospital - Barts Health Nhs Trust

    London, E11 1NR, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.